Impact of Xpert MTB/RIF for TB Diagnosis in a Primary Care Clinic with High TB and HIV Prevalence in South Africa: A Pragmatic Randomised Trial

PLoS Medicine

Volumn 11, Issue 11, 2014, Pages

  Cox, Helen S ^a,b   Mbhele, Slindile ^a   Mohess, Neisha ^a   Whitelaw, Andrew ^a,c   Muller, Odelia ^b   Zemanay, Widaad ^a   Little, Francesca ^a   Azevedo, Virginia ^d   Simpson, John ^c   Boehme, Catharina C ^e   Nicol, Mark P ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^d Khayelitsha Community Health Centre   (South Africa)

^e FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREVALENCE; PRIMARY HEALTH CARE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOUTH AFRICA; SPUTUM CYTODIAGNOSIS; TIME TO TREATMENT; TUBERCULOSIS; XPERT MTB RIF TEST; ADOLESCENT; AGED; ANTIBIOTIC RESISTANCE; COMPLICATION; GENETICS; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OUTPATIENT DEPARTMENT; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE FACILITIES; ANTIBIOTICS, ANTITUBERCULAR; DRUG RESISTANCE, BACTERIAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RIFAMPIN; SOUTH AFRICA; TIME-TO-TREATMENT; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84922341709     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001760     Document Type: Article

References (22)

1. World Health Organization (2013) Global tuberculosis report 2013. WHO/HTM/TB/2013.11. Geneva: World Health Organization.
2. Lawn SD, Ayles H, Egwaga S, Williams B, Mukadi YD, et al. (2011) Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings. Int J Tuberc Lung Dis 15: 287–295.
3. Helb D, Jones M, Story E, Boehme C, Wallace E, et al. (2010) Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 48: 229–237.
4. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, et al. (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377: 1495–1505.
5. World Health Organization (2010) Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB. Geneva: World Health Organization.
6. Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, et al. (2013) Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 1: CD009593.
7. Kwak N, Choi SM, Lee J, Park YS, Lee CH, et al. (2013) Diagnostic accuracy and turnaround time of the Xpert MTB/RIF assay in routine clinical practice. PLoS ONE 8: e77456.
8. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, et al. (2014) Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 383: 424–435.
9. City of Cape Town Strategic Development Information and Geographic Information System Department (2013) City of Cape Town—2011 Census—Khayelitsha Health District. Cape Town: City of Cape Town.
10. Médecins Sans Frontières (2011) Khayelitsha 2001–2011, activity report: 10 years of HIV/TB care at primary health care level. Geneva: Médecins Sans Frontières.
11. Enarson D, Rieder HL, Arnadottir T, Trébucq A (2000) Management of tuberculosis: a guide for low income countries. Paris: International Union Against Tuberculosis and Lung Disease.
12. Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, et al. (2010) Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 24: 563–572.
13. World Health Organization (2010) Treatment of tuberculosis: guidelines (fourth edition). Geneva: World Health Organization.
14. Lawn SD, Bekker LG, Middelkoop K, Myer L, Wood R, (2006) Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis 42: 1040–1047.
15. Getahun H, Harrington M, O'Brien R, Nunn P, (2007) Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 369: 2042–2049.
16. Fielding K, McCarthy KM, Cox H, Erasmus L, Ginindza S, et al. (2014) Xpert as the first-line TB test in South Africa: yields, initial loss to follow-up, proportion treated [abstract]. Conference on Retroviruses and Opportunistic Infections; 3–6 March 2014; Boston, Massachusetts, US. Top Antivir Med 22: 48–49.
17. Theron G, Peter J, Dowdy D, Langley I, Squire SB, et al. (2014) Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet Infect Dis 14: 527–532.
18. Ridderhof JC, van Deun A, Kam KM, Narayanan PR, Aziz MA, (2007) Roles of laboratories and laboratory systems in effective tuberculosis programmes. Bull World Health Organ 85: 354–359.
19. Cox H, Hughes J, Daniels J, Azevedo V, McDermid C, et al. (2014) Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis 18: 441–448.
20. Boyles TH, Hughes J, Cox V, Burton R, Meintjes G, et al. (2014) False-positive Xpert((R)) MTB/RIF assays in previously treated patients: need for caution in interpreting results. Int J Tuberc Lung Dis 18: 876–878.
21. Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA, (2012) Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med 9: e1001347.
22. Langley I, Lin H, Egwaga S, Doulla B, Ku C, et al. (2014) Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. Lancet Glob Health 2: e581–591.